13058_2015_630_MOESM5_ESM.pdf (4.89 MB)
Additional file 5: Figure S2. of Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion
journal contribution
posted on 2015-09-17, 05:00 authored by Hanan Elsarraj, Yan Hong, Kelli Valdez, Whitney Michaels, Marcus Hook, William Smith, Jeremy Chien, Jason Herschkowitz, Melissa Troester, Moriah Beck, Marc Inciardi, Jason Gatewood, Lisa May, Therese Cusick, Marilee McGinness, Lawrence Ricci, Fang Fan, Ossama Tawfik, Jeffrey Marks, Jennifer Knapp, Hung-Wen Yeh, Patricia Thomas, D. Carrasco, Timothy Fields, Andrew Godwin, Fariba BehbodBCL9 showed increased nuclear expression, while BCL9L expression remained cytoplasmic during ductal carcinoma in situ (DCIS) invasive transition. A Immunofluorescence staining of BCL9 (red; top panel), BCL9L (red; bottom panel), K5/K19 (green), and Hoechst (blue) in a primary sample that represents: adjacent normal glands (left), DCIS lesions (middle), and invasive ductal carcinoma (IDC) (right). BCL9 and BCL9L are conjugated to Alexa-Fluor 594 (red) and K5/K19 were conjugated to Alexa-Fluor 488 (green). Nuclei were counterstained with Hoechst. Scale bars 50 μm, × 40 objective was used. B, C RT-qPCR of BCL9 and BCL9L mRNA in epithelial cell adhesion molecule (EpCAM)-positive epithelial cells sorted from SUM225 (B) and DCIS.COM (C) mouse intraductal xenograft model (MIND) xenografts at 2, 6, and 10 weeks post-intraductal injection. The bar graphs represent fold change normalized to 2 weeks. Data are mean values ± standard error of the mean (n = 3, *p <0.05). D Representative western blot analysis of cell lysates from control and BCL9-KD-SUM225 and DCIS.COM blotted with anti-BCL9, and anti-BCL9L antibodies. β-actin was used as a loading control. The analysis showed no change in BCL9L protein levels in BCL9-KD cells compared to control cells. (PDF 5012 kb)
Funding
2014 Breast Cancer Research Foundation-AACR
History
Usage metrics
Categories
Keywords
breast cancer invasion BCL 9PDF 5012 kbscale bars 50 μ mBCL 9L protein levelsSUMBCL 9-KD cellsIDCB cell lymphoma -9DCISepithelial cell adhesion moleculemouse intraductal xenograft modelDCIS.COMBCL 9L expression10 weeks post-intraductal injectionBCL 9L mRNAvivo ductal carcinomaBCL 9anti-BCL 9L antibodiesductal carcinoma
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC